Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys - Wikidata - awgldk - TriplyDB

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

http://www.wikidata.org/entity/Q28374632

about

Adenosine A 2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease Available and emerging treatments for Parkinson's disease: a review Localization and Function of GABA Transporters GAT-1 and GAT-3 in the Basal Ganglia The adenosine A(2A) receptor of the basal ganglia Adenosine A(2A) Receptor Antagonists and Parkinson's Disease Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice.Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.Preclinical jockeying on the translational track of adenosine A2A receptors.Present and future drug treatment for Parkinson's disease.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Differential localization and function of GABA transporters, GAT-1 and GAT-3, in the rat globus pallidus.Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum.Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A(2A) Antagonist in Cocaine Dependent Subjects A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease Novel pharmacological strategies for motor complications in Parkinson's disease.GABA transporter subtype 1 and GABA transporter subtype 3 modulate glutamatergic transmission via activation of presynaptic GABA(B) receptors in the rat globus pallidus.Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease.Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.Effectiveness and tolerability of istradefylline for the treatment of restless legs syndrome: an exploratory study in five female patients.Dimerization of G protein-coupled purinergic receptors: increasing the diversity of purinergic receptor signal responses and receptor functions.Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.Future treatments for Parkinson's disease: surfing the PD pipeline.Istradefylline for the treatment of Parkinson's disease.Synaptic protein alterations in Parkinson's disease.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Adenosine A2A antagonists in Parkinson's disease: what's next?Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Non-human primate models of PD to test novel therapies.Distinctive and synergistic signaling of human adenosine A2a and dopamine D2L receptors in CHO cells.PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study.Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats.Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.

P2860

Q24201502-E0F76A6F-E043-448B-98CD-29C9A3067750 Q24633444-02380E6C-6523-4A21-95C1-F4E7ECC522A3 Q28245673-B53C5B97-3AE5-41BB-B36B-CA9ACF0C8362 Q28362817-5033945A-A538-4E67-8AB8-92415267656A Q29346492-7F3476EF-5D56-4371-AED7-09B96FEA42F2 Q33745754-20F2AAC6-452C-4799-9F06-820D919F586A Q34414817-C81F6E78-732C-4820-B291-CA4163E68EAD Q34777609-0C755A56-5A8E-4241-96A3-D8A3847F1589 Q35484805-D25F7971-C2FF-41A8-9F7D-6FE3FE77B357 Q35489240-756DA66C-166C-4C64-B734-433849183432 Q35589979-AF6D1FA9-FFD8-4224-901A-C1B2C67992E4 Q35602395-EC18D47C-192E-4F99-86CE-235FC7848A38 Q35917127-18E4C73A-E6A1-4275-8C7A-6F8DE400D92F Q35990520-80701006-725B-4699-B0F2-F60ED3A91122 Q36057652-147618C5-EAD2-4D0B-875D-5B73B8781CAF Q36120761-CBEB45C6-5688-458E-9B0C-D81EA7D815E8 Q36179607-2E7DAA3F-2098-47C0-B28F-57847BDC430F Q36573882-9EB22D3B-B515-4ED1-81CD-52236758636C Q36882447-B99E3E95-11FE-489F-B8D2-63A07AF3B212 Q37348458-C6383DA3-B83E-430A-AF87-D4F824203C2D Q37358676-4055BCAA-1291-4F9D-9C79-7E244469E296 Q37627259-5B12894C-BA0D-41F8-8121-93E1B86660A9 Q37672812-E24B37CA-4395-41F9-B862-4380DEA328E7 Q37789040-11A3F2E6-5B97-42CD-9178-F1884328C9DE Q37844573-47801D20-AF5F-4BE4-81D0-E06342C13746 Q37950428-9F33DD8B-7E7A-4CDD-9031-C1972BFCFFEC Q37965615-5904F18E-0D1E-4F8B-AE9B-82395025E8EA Q37972089-D852CB69-1DC9-453D-AB66-74D69810E7B4 Q37974709-AE9B24EA-0D13-4D70-9860-197F7C846B73 Q38010070-A802CEBE-1C06-462A-A537-A5A693B5DEF5 Q38200930-5FB95779-63E6-4336-8E05-47D1A1615183 Q38237288-27358FDF-A11F-464E-82F3-A059C76A028A Q38660240-1CE7B887-A19C-4F27-A206-58ACFD17434C Q39229450-91137DED-C0D2-4F7A-A355-24A726B89AA9 Q40367305-8C81F15F-DDA7-4204-8F1E-76BE5E0F2F84 Q42369736-40C5C4E2-928F-4DB3-9BCD-F4257C521208 Q42970953-6B962065-5FB2-4519-8269-C251F28A8BBE Q43795840-9EAA72C5-F94C-4233-8833-DA4D9253571E Q43959920-BC81B207-6475-4DCD-8510-094EA60A72A6 Q44175279-A81D100F-B9C5-4703-AE2E-DC65690E31D3

P2860

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

http://www.wikidata.org/entity/Q28374632

description

2000 nî lūn-bûn

@nan

2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@ast

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@en

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@nl

type

label

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@ast

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@en

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@nl

altLabel

Combined Use of the Adenosine ...... inesia in MPTP-Treated Monkeys

@en

prefLabel

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@ast

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@en

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@nl

P1433

Q28374632-1CCFFB3A-B06B-4981-B4A1-3AB29C4F8D33

P1476

Q28374632-7C76BDDD-E9E3-4F35-877A-C1EA3B9BEAFD

P2093

Q28374632-333FD5C6-97B4-4529-A79C-9FE6224CC730

Q28374632-414533FD-8B4D-4680-A8FD-8CF82EFDA993

Q28374632-48CB3793-F055-493C-8394-45A3CEFAC241

Q28374632-53E63035-839C-4145-A2C8-4E51B90EE788

Q28374632-8379C07C-991C-457F-9E22-F2A1740134BC

Q28374632-9C5882DF-9CC0-48AA-9E3C-1A2359DCDAA7

Q28374632-BACA262C-9469-452F-92E0-B0E83B9F5FB8

Q28374632-CE65C23C-AF5B-45F2-A4CE-FD02DE719468

P304

Q28374632-B5B5BD3D-BC4B-4867-8600-1CE61E62E476

P31

Q28374632-2B2F4AC3-E680-4EF3-BC1E-60544F84B8F3

P356

Q28374632-367CF242-6FA9-469F-AB3E-9CC2448CDAA8

P407

Q28374632-0894DE6D-EE09-493D-B19D-B1B9E65C06AC

P433

Q28374632-133E38BE-0F05-4B2F-A72A-A846AC1AFBD1

P478

Q28374632-349EFD93-91B3-4185-9504-D021344FD83A

P577

Q28374632-DA25285E-5FDA-4F56-9D1E-F2E8C14797FC

P698

Q28374632-998826ED-4952-4CA1-931E-9082E801F48F

P921

Q28374632-449234d3-e805-4dca-8d04-271243b7ca0b

Q28374632-58379890-EBDE-4C4A-87E9-9A1EACCDB661

Q28374632-80943579-EABA-42B4-938C-279FD494D4BF

P356

P1433

Experimental Neurology

P1476

Combined use of the adenosine ...... inesia in MPTP-treated monkeys

@en

P2093

H Kase

http://www.w3.org/2001/XMLSchema#string

J Nakamura

http://www.w3.org/2001/XMLSchema#string

L A Smith

http://www.w3.org/2001/XMLSchema#string

M J Jackson

http://www.w3.org/2001/XMLSchema#string

P Jenner

http://www.w3.org/2001/XMLSchema#string

R K Pearce

http://www.w3.org/2001/XMLSchema#string

T Kanda

http://www.w3.org/2001/XMLSchema#string

Y Kuwana

http://www.w3.org/2001/XMLSchema#string

P304

321-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1006/EXNR.2000.7350

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

162

http://www.w3.org/2001/XMLSchema#string

P577

2000-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10739638

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease